Literature DB >> 25704263

Does osteonecrosis of the femoral head increase surgical and medical complication rates after total hip arthroplasty? A comprehensive analysis in the United States.

Scott Yang1, Alexander Y Halim, Brian C Werner, F Winston Gwathmey, Quanjun Cui.   

Abstract

Total hip arthroplasty (THA) is a definitive option for end-stage osteonecrosis of the femoral head (ONFH). Historically, higher revision rates were observed in this population compared to THA for osteoarthritis (OA). This study provides a comprehensive evaluation of postoperative medical and surgical complications comparing THA in ONFH and OA at 90 days, 1 year, and 2 years after surgery. The PearlDiver database identified 45,002 OA and 8,429 ONFH patients who underwent THA. Mechanical complications (prosthetic loosening and osteolysis, implant failure), dislocation, renal and respiratory complications were significantly increased in the ONFH group within 2 years after THA. Pulmonary embolism rates where increased in younger ONFH patients within 2 years after THA. This data helps clinicians in the postoperative risk assessment of patients with ONFH.

Entities:  

Mesh:

Year:  2015        PMID: 25704263     DOI: 10.5301/hipint.5000224

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  9 in total

1.  Incidence and risk factors of in-hospital prosthesis-related complications following total hip arthroplasty: a retrospective Nationwide Inpatient Sample database study.

Authors:  Qinfeng Yang; Jian Wang; Yichuan Xu; Yuhang Chen; Qiang Lian; Yang Zhang
Journal:  Int Orthop       Date:  2020-06-27       Impact factor: 3.075

Review 2.  Emerging roles of MicroRNAs in osteonecrosis of the femoral head.

Authors:  Zheng Li; Bo Yang; Xisheng Weng; Gary Tse; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2017-11-12       Impact factor: 6.831

3.  Shoulder Arthroplasty for Humeral Head Avascular Necrosis Is Associated With Increased Postoperative Complications.

Authors:  M Tyrrell Burrus; Jourdan M Cancienne; Jeffrey D Boatright; Scott Yang; Stephen F Brockmeier; Brian C Werner
Journal:  HSS J       Date:  2017-05-15

4.  Clinical results of hemiarthroplasty using new bipolar cups for stage 3 or lower osteonecrosis of the femoral head: a retrospective study.

Authors:  T Abe; N Kaku; T Tabata; H Tagomori; H Tsumura
Journal:  Musculoskelet Surg       Date:  2017-11-18

5.  The Efficacy of Bisphosphonates with Core Decompression and Mesenchymal Stem Cells Compared with Bisphosphonates Alone in the Treatment of Osteonecrosis of the Hip: a Retrospective Study.

Authors:  Arianna L Gianakos; Joaquin Moya-Angeler; Shivi Duggal; Lester Zambrana; Kara G Fields; Douglas N Mintz; Charles N Cornell; Joseph M Lane
Journal:  HSS J       Date:  2016-03-17

6.  Bone-strengthening pill (BSP) promotes bone cell and chondrocyte repair, and the clinical and experimental study of BSP in the treatment of osteonecrosis of the femoral head.

Authors:  Zheng Li; Lulin Wang; Jin Wei; Liguo Zhu; Xisheng Weng; Jin Jin; Hong Xiao; Jun Zhang; Heming Wang; Guantong Shi; Lingpeng Pei; Fangde Zou; Wanqiang Zhang; Tianzun Tao; Xin Dong
Journal:  Oncotarget       Date:  2017-09-23

7.  Differential proteomic screening and identification for non-traumatic necrotic femoral osseous tissue.

Authors:  Peng Yan; Yeping Zhu; Hui Zhao; Yanyan Lu; Yuzhong Gao
Journal:  Exp Ther Med       Date:  2017-04-12       Impact factor: 2.447

8.  Unexpected dislocation following accurate total hip arthroplasty caused by excessive hip joint laxity during myasthenic crisis: a case report.

Authors:  Yoshiki Murotani; Yutaka Kuroda; Koji Goto; Toshiyuki Kawai; Shuichi Matsuda
Journal:  J Med Case Rep       Date:  2018-11-06

9.  Percutaneous autologous impaction bone graft for advanced femoral head osteonecrosis: a retrospective observational study of unsatisfactory short-term outcomes.

Authors:  Yutaka Kuroda; Manabu Nankaku; Yaichiro Okuzu; Toshiyuki Kawai; Koji Goto; Shuichi Matsuda
Journal:  J Orthop Surg Res       Date:  2021-02-17       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.